Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure

Intraday Performance and Price Movement

The stock opened sharply lower with an opening gap down of -8.7%, setting a bearish tone for the trading session. Throughout the day, Dr Reddys Laboratories Ltd remained under pressure, hitting its intraday low at Rs 1080.05, marking a fresh 52-week low. The stock closed with a day change of -3.0%, underperforming the Pharmaceuticals & Biotechnology sector by -3.84% and the broader Sensex index by a wider margin.

Volatility was notably high, with an intraday volatility of 64.86% calculated from the weighted average price, reflecting significant price swings and investor caution. This heightened volatility accompanied a third consecutive day of declines, during which the stock has lost -6.74% cumulatively.

Technical Indicators and Moving Averages

Dr Reddys Laboratories Ltd is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness across multiple timeframes signals a prevailing downtrend in the stock’s price action. The daily moving averages show a mildly bullish stance; however, weekly and monthly technical indicators such as MACD and Bollinger Bands remain bearish or mildly bearish, underscoring the ongoing pressure.

Other technical measures present a mixed picture: the weekly KST indicator is mildly bearish while the monthly KST is bullish, and Dow Theory assessments show mild bearishness weekly but mild bullishness monthly. The On-Balance Volume (OBV) indicator shows no clear trend weekly and a mildly bearish stance monthly, suggesting subdued buying interest over recent periods.

Comparative Performance Against Benchmarks

Over various time horizons, Dr Reddys Laboratories Ltd has consistently underperformed the Sensex. The stock’s 1-day return stands at -2.80% compared to the Sensex’s -0.38%. Over one week, the stock declined by -6.05% while the Sensex fell by -0.94%. The disparity widens over one month and three months, with the stock down -11.64% and -13.74% respectively, against the Sensex’s positive 0.34% and negative 1.55% returns.

Year-to-date, the stock has declined by -9.54%, slightly outperforming the Sensex’s -10.28% fall. However, longer-term returns over three, five, and ten years reveal the stock lagging the benchmark significantly, with 3-year returns at 8.73% versus Sensex’s 14.66%, 5-year returns at 6.02% against 44.33%, and 10-year returns at 59.46% compared to 175.01% for the Sensex.

Market Sentiment and Broader Index Context

The broader market environment has also been subdued. The Sensex opened 239.95 points lower and was trading at 76,476.52, down -0.36% at the time of reporting. While the Sensex remains above its 50-day moving average, the 50DMA itself is positioned below the 200DMA, indicating some underlying medium-term weakness in the benchmark index.

This cautious market backdrop has contributed to the pressure on Dr Reddys Laboratories Ltd, which is a large-cap stock within the Pharmaceuticals & Biotechnology sector. The sector itself has faced headwinds, with Dr Reddys Laboratories Ltd underperforming its peers and the sector index during the session.

Mojo Score and Rating Update

Dr Reddys Laboratories Ltd currently holds a Mojo Score of 41.0, reflecting a Sell grade as of 13 Jul 2026, a downgrade from its previous Hold rating. This change in grading indicates a deterioration in the stock’s momentum and quality metrics as assessed by MarketsMOJO’s proprietary evaluation system. The stock’s large-cap status and sector classification remain unchanged, but the rating shift aligns with the recent price weakness and technical signals.

The downgrade to Sell is consistent with the stock’s recent price action, including the fresh 52-week low and the sustained underperformance relative to the sector and benchmark indices. The combination of technical and fundamental factors has contributed to the current negative sentiment surrounding the stock.

Summary of Price Pressure and Market Dynamics

In summary, Dr Reddys Laboratories Ltd’s intraday low of Rs 1080.05 on 23 Jul 2026 reflects a continuation of downward momentum amid broad-based selling pressure. The stock’s opening gap down and high volatility underscore the unsettled trading conditions. Technical indicators and moving averages confirm a bearish trend, while comparative performance data highlights persistent underperformance versus the Sensex and sector peers.

The broader market’s cautious stance and the stock’s recent downgrade in rating further compound the challenges faced by Dr Reddys Laboratories Ltd. Investors observing the stock’s price action will note the significance of the new 52-week low and the implications of trading below all major moving averages.

Outlook on Volatility and Trading Range

Given the intraday volatility of 64.86%, the stock has experienced wide price fluctuations, which may continue to characterise trading sessions in the near term. The gap down opening and subsequent price action suggest that market participants are reacting to a combination of technical signals and broader market sentiment rather than company-specific news.

Trading below all key moving averages typically signals a lack of short-term buying support, which may keep the stock within a lower trading range until a reversal in momentum occurs. The stock’s relative weakness compared to the sector and Sensex further emphasises the current price pressure.

Conclusion

Dr Reddys Laboratories Ltd’s performance on 23 Jul 2026 highlights the challenges faced by the stock amid a cautious market environment and technical headwinds. The intraday low of Rs 1080.05 and the sustained decline over recent days reflect ongoing price pressure and subdued investor sentiment. The downgrade to a Sell grade by MarketsMOJO and the stock’s underperformance relative to benchmarks reinforce the current negative momentum.

Market participants will continue to monitor the stock’s price action and technical indicators closely as it navigates this period of volatility and downward pressure.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today